Introduction: Cancer immunotherapies have created a new generation of therapeutics to employ the immune system to attack cancer cells. However, these therapies are typically based on biologics that are nonspecific and often exhibit poor tumor penetration and dose-limiting toxicities. Nanocarriers allow the opportunity to overcome these barriers as they have the capabilities to direct immunomodulating drugs to tumor sites via passive and active targeting, decreasing potential adverse effects from nonspecific targeting. In addition, nanocarriers can be multifunctionalized to deliver multiple cancer therapeutics in a single drug platform, offering synergistic potential from co-delivery approaches. Areas covered: This review focuses on the delivery of cancer therapeutics using emerging nanocarriers to achieve synergistic results via co-delivery of immune-modulating components (i.e. chemotherapeutics, monoclonal antibodies, and genes). Expert opinion: Nanocarrier-mediated delivery of combinatorial immunotherapy creates the opportunity to fine-tune drug release while achieving superior tumor targeting and tumor cell death, compared to free drug counterparts. As these nanoplatforms are constantly improved upon, combinatorial immunotherapy will afford the greatest benefit to treat an array of tumor types while inhibiting cancer evasion pathways.
|Number of pages||13|
|Journal||Expert Opinion on Drug Delivery|
|Publication status||Published - 2022|
Bibliographical noteFunding Information:
This study was partially supported by National Science Foundation (NSF) under grant # DMR-1808251 and 2211932. The authors also acknowledge the partial support from NCI/NIH under grant # 1R01CA260140, the Wisconsin Head & Neck Cancer SPORE Grant from NIH [P50-DE026787], The Falk Medical Research Trust–Catalyst and Transformational Awards Program, and Milton J. Henrichs Chair Funds provided to S Hong. In addition, Q Hu acknowledges the start-up package support from University of Wisconsin-Madison.
© 2022 Informa UK Limited, trading as Taylor & Francis Group.
All Science Journal Classification (ASJC) codes
- Pharmaceutical Science